Inovio Pharmaceuticals (NASDAQ:INO) and Novocure (NASDAQ:NVCR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
This table compares Inovio Pharmaceuticals and Novocure’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Inovio Pharmaceuticals has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Novocure has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.
Earnings & Valuation
This table compares Inovio Pharmaceuticals and Novocure’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Inovio Pharmaceuticals||$30.48 million||7.75||-$96.97 million||($1.05)||-2.30|
|Novocure||$248.07 million||21.26||-$63.56 million||($0.69)||-79.83|
Novocure has higher revenue and earnings than Inovio Pharmaceuticals. Novocure is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
47.3% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Novocure shares are owned by institutional investors. 7.9% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Novocure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Inovio Pharmaceuticals and Novocure, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Inovio Pharmaceuticals currently has a consensus price target of $8.16, suggesting a potential upside of 238.38%. Novocure has a consensus price target of $48.57, suggesting a potential downside of 11.82%. Given Inovio Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than Novocure.
Novocure beats Inovio Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.